REESHAPE

This brand name is authorized in Nigeria.

Active ingredients

The drug REESHAPE contains one active pharmaceutical ingredient (API):

1	Orlistat UNII 95M8R751W8 - ORLISTAT
	Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides.
	Read more about Orlistat

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-7211	Capsule	REESHAPE CAPSULES CAP 120 mg 3x10	36 RNW-PP-308954 REESHAPE CAPSULES ORLISTAT USP 120MG ORLISTAT 120MG A4-7211 Drugs Imported Products 3X10 Prescription Only Medicine (POM) 1/18/2023 ADLER PRODUCTS LTD, 32, Oduyemi Street,, Ikeja MEYER ORGANICS PVT. LTD., 10-D,2ND PHASE, PEENYA INDUSTRIAL AREA, BANGALORE-560 058, INDIA., India	27/03/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A08AB01	Orlistat	A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AB Peripherally acting antiobesity products
Discover more medicines within A08AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-7211